4th Quarter - Report

ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP

Firm
Client
Income
—
Expenses
$510,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

FDA Patent Settlement legislation Intellectual property and patent issues S. 340, H.R. 965 CREATES Act S. 1209, REMEDY Act S. 1224, H.R. 2374, Stop STALLING Act

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES —
HELEN DWIGHT —
JULIE GARNER —
NATALIE MORRIS —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES

Bills named: H.R. 965 (116th), S. 1209 (116th), H.R. 2374 (116th), S. 340 (116th), S. 1224 (116th)

Health Issues HCR

Value of Prescription Drugs Drug Pricing Transparency Oncology Care Model Personalized Medicine Diagnostics S. 1895, Lower Health Care Costs Act HR 3 Drug pricing bill Rebate Reform USMCA

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES —
HELEN DWIGHT —
JULIE GARNER —
NATALIE MORRIS —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 3 (116th), S. 1895 (116th)

Medicare/Medicaid MMM

Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Changes to the Medicaid Drug Rebate Program (AMP Cap) Medicare Part B Intl. Pricing Index ANPRM -14 Day Rule End State Renal Disease PPS H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs Final Rule: Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES .
HELEN DWIGHT —
JULIE GARNER —
NATALIE MORRIS —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 107 (116th)

Pharmacy PHA

Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House, CMS Price Transparency, Senate & House Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program International Pricing Index Model (IPI) H.R. 1499, Protecting Consumer Access to Generic Drugs Act S. 1416, Affordable prescriptions for Patients Act S. 64, H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act NPRM: Importation of Prescription drugs

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES —
HELEN DWIGHT —
JULIE GARNER —
NATALIE MORRIS —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC)

Bills named: S. 64 (116th), S. 1416 (116th), H.R. 2375 (116th), H.R. 1499 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.